期刊文献+

金属硫蛋白及其基因在人胰腺癌细胞株中的表达及意义 被引量:7

Metallothionein and Its Isoform Genes Expression in the Human Pancreatic Cancer Cell Strains and Their Function
下载PDF
导出
摘要 目的比较金属硫蛋白(MT)及其基因在人胰腺癌细胞株和耐药细胞株中的表达,探讨MT表达与胰腺癌细胞耐药的关系。方法采用逆转录聚合酶链反应(RT-PCR)检测MT基因的mRNA表达情况,采用镉/血红蛋白饱和-电化学分析法检测MT表达情况。结果人胰腺癌细胞株中的MT可由MT-1A、MT-1B、MT-1E、MT-1F、MT-1G、MT-1X及MT-2A基因编码;MT-1B、MT-1E、MT-1X及MT-2A基因和MT在人胰腺癌耐药细胞株中的表达水平显著增高(P<0.05)。结论人胰腺癌细胞株中的MT及其基因表达与胰腺癌细胞株的增殖及化疗耐药性相关。 Objective To compare the expression of metallothionein (MT) genes and proteins in six human pancreatic cancer cell strains and two human pancreatic cancer drug-resistant cell strains and to explore the relationship between the expression of the MT and pancreatic cancer cell chemoresistance. Methods Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine the MT isoform-specific mRNA, and cadmium/hemoglobin saturation-electrochemistry to determine MT protein levels. Results MT protein expression in the pancreatic cancer cell strains was encoded by MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1X, and MT-2A genes. The expression of MT proteins was upregulated and MT-1B, MT-1E, MT-1X, MT-2A genes overexpressed in human pancreatic cancer drug-resistant cell lines (P〈0.05). Conclusion Expressions of MT proteins and genes correlate with the proliferation and chemoresistance of human pancreatic cancer cell strains.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2005年第5期619-623,共5页 Acta Academiae Medicinae Sinicae
基金 国家自然科学基金(30371389)资助~~
关键词 金属硫蛋白 逆转录聚合酶链反应 细胞培养 胰腺癌 metallothionein reverse transcriptase-polymerase chain reaction cell culture pancreatic cancer
  • 相关文献

参考文献14

  • 1Miles AT, Hawksworth GM, Beattie JH, et al. Induction,regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol, 2000,35(1):35-70.
  • 2张立阳,赵玉沛,廖泉,郭俊超,刘子文,张太平.维拉帕米逆转胰腺癌化疗耐药的研究[J].中华肝胆外科杂志,2004,10(4):263-266. 被引量:9
  • 3Onosaka S, Tanaka K, Doi M, et al. A simplified procedure for determination of metallothionein in animal tissues. Eisei Kagaku, 1978, 24(3): 128-131.
  • 4Hijova E. Metallothioneins and zinc: their functions and interactions. Bratisl Lek Listy, 2004, 105(5-6):230-234.
  • 5Cherian MG, Apostolova MD. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol (Noisy-le-grand), 2000, 46(2):347-356.
  • 6Theocharis SE, Margeli AP, Klijanienko JT, et al. Metallothionein expression in human neoplasia. Histopathology,2004, 45(2):103-118.
  • 7Garrett SH, Somji S, Todd JH, et al. Differential expression of human metallothionein isoform Ⅰ mRNA in human proximal tubule cells exposed to metals. Environ Health Perspect, 1998, 106(12):825-832.
  • 8Vandeghinste N, Proost P, De Ley M. Metallothionein isoform gene expression in zinc-treated human peripheral blood lymphocytes. Cell Mol Biol (Noisy-le-grand), 2000,46(2):419-433.
  • 9Barnes NL, Ackland ML, Cornish EJ. Metallothionein isoform expression by breast cancer cells. Int J Biochem Cell Biol, 2000, 32(8):895-903.
  • 10Chun JH, Kim HK, Kim E, et al. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res, 2004, 64(14):4703-4706.

二级参考文献14

  • 1Hirofumi S,Gakuji O,Shinji A,et al. Immunohistochemical localization of P-Glycoprotein and expression of the multidrug resistance-1gene in human pancreatic cancer: relevance to indication of better prognosis . Jpn J Cancer Res, 1996,87:641-649.
  • 2Gebaccer T, Ridwelski K, Fahlbe J. Locoregional and systemic therapy of advanced pancreatic carcinoma. Langenbecks Arch Chir,1988,115:1344-1347.
  • 3Ludescher C, Thaler J, Drach D, et al. Detection of P-glycoprotein in human tumor samples using rhodamine 123. Br J Haematol, 1992,82:161-168.
  • 4Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth and cell kill. J Immun Method, 1989,119-203.
  • 5Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res, 1970,30:1174-1184.
  • 6Ozols RF, Cunnion RE, Klecher RW, et al. Verapamil and adriamycin in the treatment of drug-resistance ovarian cancer patients. J Clin Oncol, 1987,5:641-647.
  • 7Thurlimann B, Kroger M, Greiner J, et al. Decverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol,1995,121:R3-6.
  • 8Nazlio O,Tansug T,Bozdag AD,et al. Locoregional chemotherapy in pancratic cancer. Hepatogastroenterology, 1999, 46:479-482.
  • 9Filipits M, Suchomel RW, Dekan G,et al. Expression of the multidrug resistance-associated protein gene in colorectal carcinomas. Br J Cancer,1997,75:208-212.
  • 10Verelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst,1991,83:111-116.

共引文献8

同被引文献61

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部